Kurozumi Sasagu

Last updated: Nov 20, 2019 at 01:58

Name	Kurozumi Sasagu
Affiliation	Gunma University
Job title	Assistant Professor

Research Interests

Medical oncology(37) , Pathology(174) , Artificial intelligence(342) , Bioinformatics(273) , breast cancer(126)

Research Areas

Basic medicine / Human pathology /
Biomedical engineering / Medical systems /
Clinical surgery / General surgery / Breast Cancer

Published Papers

Plain Text

Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.

Kariri YA, Joseph C, Kurozumi S, Toss MS, Alsaleem M, Raafat S, Mongan NP, Aleskandarany MA, Green AR, Rakha EA

Breast cancer research and treatment Nov 2019 [Refereed]

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.

Aljohani AI, Toss MS, Kurozumi S, Joseph C, Aleskandarany MA, Miligy IM, Ansari RE, Mongan NP, Ellis IO, Green AR, Rakha EA

Breast cancer research and treatment Oct 2019 [Refereed]

Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.

Kurozumi S, Alsaeed S, Orah N, Miligy IM, Joseph C, Aljohani A, Toss MS, Fujii T, Shirabe K, Green AR, Aleskandarany MA, Rakha EA

Breast cancer research and treatment Nov 2019 [Refereed]

Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.

Joseph C, Al-Izzi S, Alsaleem M, Kurozumi S, Toss MS, Arshad M, Goh FQ, Alshankyty IM, Aleskandarany MA, Ali S, Ellis IO, Mongan NP, Green AR, Rakha EA

British journal of cancer 121(9) 776-785 Sep 2019 [Refereed]

Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.

Kurozumi S, Inoue K, Matsumoto H, Fujii T, Horiguchi J, Oyama T, Kurosumi M, Shirabe K

Scientific reports 9(1) 16662 Nov 2019 [Refereed]

β₂-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer.

Kurozumi S, Kaira K, Matsumoto H, Hirakata T, Yokobori T, Inoue K, Horiguchi J, Katayama A, Koshi H, Shimizu A, Oyama T, Sloan EK, Kurosumi M, Fujii T, Shirabe K

Breast cancer research and treatment 177(3) 603-610 Oct 2019 [Refereed]

The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts.

Alsaleem M, Toss MS, Joseph C, Aleskandarany M, Kurozumi S, Alshankyty I, Ogden A, Rida PCG, Ellis IO, Aneja R, Green AR, Mongan NP, Rakha EA

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 32(7) 967-976 Jul 2019 [Refereed]

Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.

Kurozumi S, Joseph C, Raafat S, Sonbul S, Kariri Y, Alsaeed S, Pigera M, Alsaleem M, Nolan CC, Johnston SJ, Aleskandarany MA, Ogden A, Fujii T, Shirabe K, Martin SG, Alshankyty I, Mongan NP, Ellis IO, Green AR, Rakha EA

Breast cancer research and treatment 176(1) 63-73 Jul 2019 [Refereed]

Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer.

Kurozumi S, Yamaguchi Y, Matsumoto H, Inoue K, Kurosumi M, Oyama T, Horiguchi J, Fujii T, Shirabe K

Medical molecular morphology 52(2) 90-98 Jun 2019 [Refereed]

A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.

Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani A, Raafat S, Alsaleem M, Ogden A, Johnston SJ, Aleskandarany MA, Fujii T, Shirabe K, Caldas C, Ashankyty I, Dalton L, Ellis IO, Desmedt C, Green AR, Mongan NP, Rakha EA

British journal of cancer 120(12) 1129-1136 Jun 2019 [Refereed]

Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer.

Handa T, Katayama A, Yokobori T, Yamane A, Fujii T, Obayashi S, Kurozumi S, Kawabata-Iwakawa R, Gombodorj N, Nishiyama M, Asao T, Shirabe K, Kuwano H, Oyama T

International journal of oncology 54(3) 833-844 Mar 2019 [Refereed]

Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis.

Kurozumi S, Matsumoto H, Kurosumi M, Inoue K, Fujii T, Horiguchi J, Shirabe K, Oyama T, Kuwano H

Oncology letters 17(3) 2647-2656 Mar 2019 [Refereed]

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.

Kurozumi S, Inoue K, Matsumoto H, Fujii T, Horiguchi J, Oyama T, Kurosumi M, Shirabe K

Scientific reports 9(1) 1583 Feb 2019 [Refereed]

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy.

Kurozumi S, Yamaguchi Y, Matsumoto H, Kurosumi M, Hayashi SI, Fujii T, Horiguchi J, Shirabe K, Inoue K

PloS one 14(5) e0217279 2019 [Refereed]

Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3.

Toda H, Kurozumi S, Kijima Y, Idichi T, Shinden Y, Yamada Y, Arai T, Maemura K, Fujii T, Horiguchi J, Natsugoe S, Seki N

Journal of human genetics 63(12) 1197-1210 Dec 2018 [Refereed]

Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.

Sonbul SN, Aleskandarany MA, Kurozumi S, Joseph C, Toss MS, Diez-Rodriguez M, Nolan CC, Mukherjee A, Martin S, Caldas C, Ellis IO, Green AR, Rakha EA

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 31(11) 1675-1682 Nov 2018 [Refereed]

Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.

Kurozumi S, Joseph C, Sonbul S, Aleskandarany MA, Pigera M, Alsaleem M, Alsaeed S, Kariri Y, Nolan CC, Diez-Rodriguez M, Johnston S, Mongan NP, Fujii T, Shirabe K, Martin SG, Ellis IO, Green AR, Rakha EA

Breast cancer research and treatment 172(1) 61-68 Nov 2018 [Refereed]

Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.

Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M

Breast cancer research and treatment 171(3) 675-683 Oct 2018 [Refereed]

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair.

Johnston SJ, Ahmad D, Aleskandarany MA, Kurozumi S, Nolan CC, Diez-Rodriguez M, Green AR, Rakha EA

BMC cancer 18(1) 1027 Oct 2018 [Refereed]

Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.

Kurozumi S, Joseph C, Sonbul S, Gorringe KL, Pigera M, Aleskandarany MA, Diez-Rodriguez M, Nolan CC, Fujii T, Shirabe K, Kuwano H, Storr S, Martin SG, Ellis IO, Green AR, Rakha EA

Breast cancer research and treatment 170(3) 525-533 Aug 2018 [Refereed]

Relationship Between FDG Uptake and Neutrophil/Lymphocyte Ratio in Patients with Invasive Ductal Breast Cancer.

Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Shirabe K

Anticancer research 38(8) 4927-4931 Aug 2018 [Refereed]

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.

Kurozumi S, Matsumoto H, Inoue K, Tozuka K, Hayashi Y, Kurosumi M, Oyama T, Fujii T, Horiguchi J, Kuwano H

PloS one 13(8) e0201846 2018 [Refereed]

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index

Kurozumi, Sasagu; Matsumoto, Hiroshi; Hayashi, Yuji; Tozuka, Katsunori; Inoue, Kenichi; Horiguchi, Jun; Takeyoshi, Izumi; Oyama, Tetsunari; Kurosumi, Masafumi

BMC CANCER 17 354 2017

Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes

Kurozumi, Sasagu; Yamaguchi, Yuri; Kurosumi, Masafumi; Ohira, Miki; Matsumoto, Hiroshi; Horiguchi, Jun

JOURNAL OF HUMAN GENETICS 62(1) 15-24 2017

Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer

Kurozumi, Sasagu; Fujii, Takaaki; Matsumoto, Hiroshi; Inoue, Kenichi; Kurosumi, Masafumi; Horiguchi, Jun; Kuwano, Hiroyuki

MEDICAL MOLECULAR MORPHOLOGY 50(4) 185-194 2017

Clinicopathological Features of Ductal Carcinoma In Situ from F-18-FDG-PET Findings

Fujii, Takaaki; Yanai, Keiko; Tokuda, Shoko; Nakazawa, Yuko; Kurozumi, Sasagu; Obayashi, Sayaka; Yajima, Reina; Hirakata, Tomoko; Kuwano, Hiroyuki

ANTICANCER RESEARCH 37(9) 5053-5056 2017

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.

Kurozumi S, Padilla M, Kurosumi M, Matsumoto H, Inoue K, Horiguchi J, Takeyoshi I, Oyama T, Ranger-Moore J, Allred DC, Dennis E, Nitta H

Breast cancer research and treatment 158(1) 99-111 Jul 2016 [Refereed]

Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer

Kurozumi, Sasagu; Yamaguchi, Yuri; Hayashi, Shin-ichi; Hiyoshi, Hiromi; Suda, Tetsuji; Gohno, Tatsuyuki; Matsumoto, Hiroshi; Takei, Hiroyuki; Horiguchi, Jun; Takeyoshi, Izumi; Oyama, Tetsunari; Kurosumi, Masafumi

CANCER MEDICINE 5(8) 1873-1882 2016

Clinical Significance of F-18-FDG-PET in Invasive Lobular Carcinoma

Fujii, Takaaki; Yajima, Reina; Kurozumi, Sasagu; Higuchi, Toru; Obayashi, Sayaka; Tokiniwa, Hideaki; Nagaoka, Rin; Takata, Daisuke; Horiguchi, Jun; Kuwano, Hiroyuki

ANTICANCER RESEARCH 36(10) 5481-5485 2016

ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide conco

Kurozumi S, Inoue K, Takei H, Matsumoto H, Kurosumi M, Horiguchi J, Takeyoshi I, Oyama T

BMC cancer 15 622 Sep 2015 [Refereed]

[A case of aromatase inhibitor-tolerant metastatic breast cancer revealing complete remission with high-dose toremifene therapy].

Kurozumi S, Takeo T, Ikeda F, Horiguchi J, Takeyoshi I, Ito H

Gan to kagaku ryoho. Cancer & chemotherapy 38(1) 93-96 Jan 2011 [Refereed]

Misc

Plain Text1 2 3 4 >

頸部、腋窩領域のリンパ節転移との鑑別を要したSchwannomaの3例

喜多碧, 徳田尚子, 中澤祐子, 黒住献, 尾林紗弥香, 矢島玲奈, 小山徹也, 藤井孝明

日本内分泌外科学会雑誌 36(Suppl.3) S334-S334 Sep 2019

原発性乳癌におけるFDG集積とPD-L1及びVEGFとの関連性

平方智子, 藤井孝明, 片山彩香, 矢島玲奈, 尾林紗弥香, 黒住献, 中澤祐子, 徳田尚子, 矢内恵子, 本田周子, 横堀武彦, 飯野佑一, 調憲

日本乳癌学会総会プログラム抄録集 27回 584-584 Jul 2019

手術不能又は再発乳癌に対するTS-1とCyclophosphamide逐次療法の第II相臨床試験に関する研究

矢内恵子, 徳田尚子, 中澤祐子, 黒住献, 尾林紗弥香, 矢島玲奈, 平方智子, 飯野祐一, 藤井孝明

日本乳癌学会総会プログラム抄録集 27回 495-495 Jul 2019

乳癌におけるFDG集積とPLRの関連

喜多碧, 矢内恵子, 徳田尚子, 中澤祐子, 黒住献, 尾林紗弥香, 矢島玲奈, 平方智子, 小山徹也, 藤井孝明

日本乳癌学会総会プログラム抄録集 27回 585-585 Jul 2019

TC療法による脱毛の長期経過　1年後毛髪の変化に関する前向き観察研究

一場慶, 平方智子, 矢島玲奈, 尾林紗弥香, 黒住献, 中澤祐子, 徳田尚子, 矢内恵子, 藤井孝明

日本乳癌学会総会プログラム抄録集 27回 646-646 Jul 2019